T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
World game at war: why some European nations have threatened a World Cup boycott 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
TUCSON, Ariz., April 27, 2018 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will report its financial results for the quarter ended March 31, 2018 after the market close on Thursday, May 10. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.
| Conference Call & Webcast Details | ||
| Date: | Thursday, May 10 | |
| Time: | 4:30pm Eastern Time | |
| Toll Free: | 866-548-4713 | |
| International: | 323-794-2093 | |
| Conference ID: | 5477857 | |
| Webcast: | http://public.viavid.com/index.php?id=129155 | |
About HTG:
HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.
CONTACT:
Ashley Robinson
LifeSci Advisors, LLC
617-775-5956
[email protected]
TJ Johnson
President/CEO
HTG Molecular Diagnostics
520-547-2827 x130
[email protected]
